TRIB — Trinity Biotech plc

Trinity Biotech (TRIB) Q3 2024 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q3 2024 revenue was $15.2 million, a 3% increase year-over-year. Point-of-care revenue rose significantly by 60% to $4.3 million, driven by TrinScreen HIV sales of approximately $2.4 million. Clinical laboratory revenues decreased by 9% to $10.8 million, primarily due to a 70% drop in hemoglobin product sales.
• Gross Profit: Gross profit for the quarter was $5.3 million, with a gross margin of 35%.
• Operating Loss: The operating loss improved to $2.6 million from $4.5 million in Q3 2023.
• Net Loss: The net loss post-tax was $4.8 million, down from $6.7 million in the prior year.
• Adjusted EBITDASO: Reported at a loss of $1.4 million, an improvement from a $3.5 million loss in Q3 2023.
• Cash Position: Cash decreased from $5.3 million at the end of Q2 to $2.8 million at the end of Q3, with operational cash outflows of $3.6 million.

2. Strategic Updates and Business Highlights

• Continuous Glucose Monitor (CGM): The company is progressing towards the commercial launch of a next-generation CGM aimed at reducing costs and waste, with a focus on user experience and additional physiological data capture.
• Acquisitions: Trinity Biotech has acquired technologies for prostate cancer and preeclampsia testing, leveraging FDA changes to enhance their market position. The acquisitions are expected to create significant value, with revenue generation anticipated for the second half of 2025.
• Transformation Plan: The company is executing a comprehensive transformation plan aimed at enhancing profitability through cost reductions, manufacturing consolidation, and operational efficiencies. Key milestones include the transfer of manufacturing to offshore partners and the consolidation of operations to fewer sites.

3. Forward Guidance and Outlook

• The company reiterated its guidance for TrinScreen sales of approximately $10 million for 2024, expecting about $3 million in Q4.
• Annualized run rate EBITDASO is projected to reach approximately $20 million, with revenues of around $75 million by Q2 2025.
• Management anticipates a significant step change in profitability as transformation initiatives are completed by early 2025.

4. Challenges and Points of Concern

• Revenue Variability: There is ongoing uncertainty regarding order patterns for TrinScreen HIV, which can lead to fluctuations in revenue.
• Declining Hemoglobin Sales: The significant drop in hemoglobin product sales raises concerns about the stability of this revenue stream.
• Cash Burn: The decrease in cash reserves and operational cash outflows highlight potential liquidity concerns, especially with ongoing restructuring costs.
• Execution Risks: The ambitious transformation plan requires careful execution in a highly regulated environment, and delays could impact financial performance.

5. Notable Q&A Insights

• Management confirmed expectations for approximately $3 million in TrinScreen revenue for Q4 2024.
• The company is cautious about instrument sales, indicating a strategic shift towards promoting new product offerings rather than pushing for immediate sales of existing instruments.
• There is optimism about the timeline for new tests, with the preeclampsia test expected to generate revenue in late 2025 and the prostate cancer test projected for 2026.
• The share count impact from recent acquisitions remains uncertain, with management promising to provide further details.

Overall, Trinity Biotech is navigating a transformative phase with a focus on long-term growth through innovative products and strategic acquisitions, while also addressing immediate financial challenges and operational efficiencies.